Medipal Holdings (7459 JP): Largest Investor’s Pressure Aims to Enhance Shareholder Value
Medipal's largest shareholder Silchester demanded that Medipal convene an EGM to consider four proposals, including dismissal of Director Shuichi...
89 Views
Paltac (8283 JP): MediPal (7459 JP)’s Attractive Tender Offer
The offer is attractive as it represents an all-time high and is above the midpoint of the target IFA’s DCF valuation range. This is a done deal.
293 Views
APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm
NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...
92 Views
Primer: Medipal Holdings (7459 JP) - May 2026
Medipal Holdings is a dominant player in Japan's stable but low-margin pharmaceutical wholesale industry, leveraging its vast scale and...
120 Views
Medipal Holdings (7459 JP): Paltac (8283 JP) Acquisition to Release Margin Pressure
Medipal Holdings plans to acquire a minimum of 8.7M shares of Paltac Corporation to make it a wholly owned subsidiary, at ¥6,650 per share, aiming...
134 Views